Thyroid cancer is a complex beast, and doctors are always looking for better ways to fight it. As new, super-specific treatments become available, it is crucial to identify the right patients who will benefit from them. This is where biomarker testing comes in. It is a fancy term for checking the unique features of a tumor to predict how it will behave and respond to treatment.

In Europe, guidelines for managing advanced thyroid cancer are already in place. But there is a gap. There is a need for clear, standardized rules for molecular testing across the board. This means figuring out what to test for, when to test, and who should be tested. A group of experts got together to create some consensus testing plans. They included endocrinologists, oncologists, molecular biologists, and pathologists. Their goal was to provide clear recommendations for doctors treating advanced thyroid cancer.

Let us break down the plans for the three main types of thyroid cancer.

Differentiated thyroid cancer is the most common type. For these patients, comprehensive testing using DNA and RNA next-generation sequencing is recommended. This is especially important for those whose cancer has progressed or is resistant to radioactive iodine treatment.

Medullary thyroid cancer is less common but can be aggressive. For these patients, RET-germline testing is recommended at diagnosis. For those with high-risk features or progressing disease, somatic RET testing with next-generation sequencing should be considered before starting systemic treatment.

Anaplastic thyroid cancer is the most aggressive type. For these patients, molecular reflex testing for BRAF mutations is recommended at diagnosis. If the BRAF test is negative, DNA and RNA next-generation sequencing should follow.

The experts also provided recommendations on using tumor tissue for testing and the benefits of centralizing molecular testing. This involves multidisciplinary tumor boards, where experts from different fields come together to discuss and decide on the best treatment plans.

The beauty of these consensus testing algorithms is that they provide a standardized approach to molecular testing in thyroid cancer. This can help improve treatment outcomes and ensure that patients receive the most appropriate and effective therapies. It is a step forward in the fight against thyroid cancer.

However, it is important to note that these are just recommendations. More research is needed to validate these testing algorithms and to continue improving the management of advanced thyroid cancer. The field of oncology is always evolving, and so should the guidelines.

Navigating Thyroid Cancer: The Power of Predictive Biomarker Testing

Actions